In a landmark stride toward enhancing gene therapy, scientists from the Children’s Medical Research Institute (CMRI) have unveiled a revolutionary method for evaluating adeno-associated viral vector-based (AAV) gene therapies using whole human liver explants. This pioneering approach, leaded by Dr. Leszek Lisowski, the head of CMRI’s translational vectorology unit and the communicating author of the publication, utilizes an ex situ normothermic perfusion system. Detailed in Nature Communications, this innovation marks a critical step forward in developing clinically predictive model systems, crucial for the advancement of personalized medicine.

This research tackles the inherent complexities of liver-directed gene therapies by testing a suite of fourteen natural and bioengineered AAV vectors directly within human livers, under conditions both with and without neutralizing human sera. The standout performers, AAV-SYD12 and AAV-LK03, demonstrated superior cellular uptake and transgene expression under non-neutralizing conditions.

However, the study also shed light on the challenge posed by anti-AAV neutralizing antibodies, which extensively neutralized vectors of human origin, like those derived from AAV2/AAV3b, highlighting the efficiency of AAV8-derived variants.

Originating from a collaborative effort between CMRI’s translational vectorology research unit and a team at Royal Prince Alfred Hospital, this innovative approach addresses the limitations of traditional preclinical models in replicating human physiological conditions and predicting clinical outcomes. By directly assessing gene therapeutic function in the target organ, this model not only paves the way for more accurate dose estimation and side effect identification but also opens new avenues for the development of liver-focused gene therapies, potentially revolutionizing treatment strategies for various inherited diseases.

Reference::
Cabanes-Creus, M., Liao, S.H.Y., Gale Navarro, R. et al. Harnessing whole human liver ex situ normothermic perfusion for preclinical AAV vector evaluation. Nat Commun 15, 1876 (2024). https://doi.org/10.1038/s41467-024-46194-y
https://www.nature.com/articles/s41467-024-46194-y
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Scientists develop potential stealth cancer therapy

Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE